Claire McCann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Claire McCann has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer Woo
Varian, a Siemens Healthineers Company, Palo Alto, CA, USA
2 shared publications - Kenneth Russell
Varian Medical Systems, LLC, A Siemens Healthineers Company, Palo Alto, CA, United States
2 shared publications A Khalessi
Neurosurgery, UCSD, La Jolla, CA, USA
1 shared publicationA Wali
Neurosurgery, UCSD, La Jolla, CA, USA
1 shared publicationA. Carlile
1 shared publication- Alex T. Price
Department of Radiation Oncology University Hospitals Seidman Cancer Center Case Western Reserve University School of Medicine Cleveland Ohio USA
1 shared publication
Latest Publications
- Open Access
- 23 February 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e84607
Stereotactic Adaptive Radiation Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer to Minimize Gastrointestinal Toxicity (ARTIA-Pancreas): Protocol for a Single-Arm Prospective Trial
Background: Computed tomography (CT)–guided online stereotactic adaptive radiotherapy (CT-STAR) allows for ablative radiation doses to be delivered to selected patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) or unresectable pancreatic cancer. However, the use of CT-STAR to deliver an ablative dose to the pancreas while minimizing gastrointestinal (GI) side effects to reduce acute and late toxicity rates compared to historic controls has yet to be prospectively evaluated. Objective: The primary objective of this prospective, single-arm, multicenter phase 2 clinical trial (Adaptive Radiation Therapy Individualized Approach [ARTIA]–Pancreas) is to evaluate the rate of acute grade 3+ GI toxicity in patients with BR/LAPC treated with ablatively dosed CT-STAR compared to historical controls. Methods: Patients with histologically or cytologically confirmed BR, locally advanced, or medically inoperable pancreatic adenocarcinoma are eligible for participation. Consenting and eligible patients will be treated with CT-STAR, delivering 5 fractions over 1 to 2 weeks with daily adaptation based on anatomic changes observed with onboard cone beam CT imaging. The primary end point of this trial is the rate of acute patient-reported grade 3+ treatment-related GI toxicities, assessed at 90 days post CT-STAR and compared to a historical control rate of 20%. The key powered secondary end point is the rate of long-term patient-reported grade 3+ treatment-related GI toxicities, evaluated at 12 months post CT-STAR and compared to a historical control rate of 25%. Additional secondary end points include overall survival, local (in-field) control rates, and distant progression-free survival at 1 and 2 years post CT-STAR. Results: Study completion is anticipated in February 2029, and the final study results will be published upon completion of the study. Conclusions: ARTIA-Pancreas represents the first prospective phase 2 clinical trial to evaluate whether CT-STAR can reduce the rate of acute patient-reported GI toxicities in patients with BR/LAPC compared to historical controls. Findings from this clinical trial will provide evidence for safely and effectively incorporating ablatively dosed adaptive radiotherapy into treatment regimens for this population.
- 23 February 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e84607
Open AccessStereotactic Adaptive Radiation Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer to Minimize Gastrointestinal Toxicity (ARTIA-Pancreas): Protocol for a Single-Arm Prospective Trial
Background: Computed tomography (CT)–guided online stereotactic adaptive radiotherapy (CT-STAR) allows for ablative radiation doses to be delivered to selected patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) or unresectable pancreatic cancer. However, the use of CT-STAR to deliver an ablative dose to the pancreas while minimizing gastrointestinal (GI) side effects to reduce acute and late toxicity rates compared to historic controls has yet to be prospectively evaluated. Objective: The primary objective of this prospective, single-arm, multicenter phase 2 clinical trial (Adaptive Radiation Therapy Individualized Approach [ARTIA]–Pancreas) is to evaluate the rate of acute grade 3+ GI toxicity in patients with BR/LAPC treated with ablatively dosed CT-STAR compared to historical controls. Methods: Patients with histologically or cytologically confirmed BR, locally advanced, or medically inoperable pancreatic adenocarcinoma are eligible for participation. Consenting and eligible patients will be treated with CT-STAR, delivering 5 fractions over 1 to 2 weeks with daily adaptation based on anatomic changes observed with onboard cone beam CT imaging. The primary end point of this trial is the rate of acute patient-reported grade 3+ treatment-related GI toxicities, assessed at 90 days post CT-STAR and compared to a historical control rate of 20%. The key powered secondary end point is the rate of long-term patient-reported grade 3+ treatment-related GI toxicities, evaluated at 12 months post CT-STAR and compared to a historical control rate of 25%. Additional secondary end points include overall survival, local (in-field) control rates, and distant progression-free survival at 1 and 2 years post CT-STAR. Results: Study completion is anticipated in February 2029, and the final study results will be published upon completion of the study. Conclusions: ARTIA-Pancreas represents the first prospective phase 2 clinical trial to evaluate whether CT-STAR can reduce the rate of acute patient-reported GI toxicities in patients with BR/LAPC compared to historical controls. Findings from this clinical trial will provide evidence for safely and effectively incorporating ablatively dosed adaptive radiotherapy into treatment regimens for this population.
- Open Access
- 17 September 2023
- Published by Elsevier in European Urology Open Science
- Vol. 55, S9
Long term oncologic and procedural outcomes following percutaneous microwave ablation of small renal masses
- 17 September 2023
- Published by Elsevier in European Urology Open Science
- Vol. 55, S9
Open AccessLong term oncologic and procedural outcomes following percutaneous microwave ablation of small renal masses
- Open Access
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A131.2-A132
E-095 Serial dilation technique for ulnar artery access in neuro-endovascular procedures: technical report and systematic review of the literature
Background For rare neuro-endovascular cases in which transfemoral access is not feasible and the palmar circulation is insufficient for radial artery access, ulnar artery access may be considered. Materials and Methods Prior to catheterization, nitroglycerine paste was applied along the distribution of the right ulnar artery. Heparin and verapamil were administered to the ulnar artery via the microdilator. Subsequent serial dilation to 7-French was performed. The 7-French radialsheath was advanced into the ulnar artery over the Nitrex wire. A diagnostic angiogram was performed using a 4-French 120 cm angled glide diagnostic catheter. The sheath was exchanged for a Neuron MAX 88 guide catheter, and a triaxial system consisting of an ACE 60 Penumbra reperfusion catheter, a 3MAX Penumbra reperfusion catheter, and Synchro2 standard wire was inserted. A three-pass mechanical thrombectomy involving aspiration and stent-retriever techniques yielded at TICI 3 result. Results 67-year-old male developed left MCA syndrome in the setting of an infected abdominal aortic endograft. A transfemoral approach was ruled out due to concern for crossing the infected endograft. Allen test and ultrasound demonstrated that the right radial artery was of adequate size for access, but the ulnar artery was insufficient to support the palmar arch. Mechanical thrombectomy via ulnar artery access was performed to preserve the dominant radial artery. Systematic review of the literature yielded 2 case series of transulnar neurovascular procedures. Access site complications were rare and included 3 access site hematomas and 1 ulnar artery occlusion. Conclusion We report our technique of serial dilation of the ulnar artery for neuroendovascular procedures and provide a systematic review of the literature for complication avoidance in ulnar artery access. Literature review of ulnar artery access for endovascular neuro-intervention A) Ulnar artery angiogram demonstrates normal-caliber radial artery (black arrow) with small caliber ulnar artery (white arrow). B) Left internal carotid artery angiogram demonstrates left M1 segment middle cerebral artery occlusion. C) Left common carotid artery angiogram demonstrates recanalization of left M1 segment after thrombectomy. D) Ulnar artery angiogram demonstrates occlusion of the ulnar artery (white arrow) in the forearm with normal caliber radial artery (black arrow) Disclosures M. Brandel: None. A. Wali: None. C. McCann: None. B. Tucker: None. S. Olson: None. J. Steinberg: None. D. Santiago-Dieppa: None. A. Khalessi: None. J. Pannell: None.
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A131.2-A132
Open AccessE-095 Serial dilation technique for ulnar artery access in neuro-endovascular procedures: technical report and systematic review of the literature
Background For rare neuro-endovascular cases in which transfemoral access is not feasible and the palmar circulation is insufficient for radial artery access, ulnar artery access may be considered. Materials and Methods Prior to catheterization, nitroglycerine paste was applied along the distribution of the right ulnar artery. Heparin and verapamil were administered to the ulnar artery via the microdilator. Subsequent serial dilation to 7-French was performed. The 7-French radialsheath was advanced into the ulnar artery over the Nitrex wire. A diagnostic angiogram was performed using a 4-French 120 cm angled glide diagnostic catheter. The sheath was exchanged for a Neuron MAX 88 guide catheter, and a triaxial system consisting of an ACE 60 Penumbra reperfusion catheter, a 3MAX Penumbra reperfusion catheter, and Synchro2 standard wire was inserted. A three-pass mechanical thrombectomy involving aspiration and stent-retriever techniques yielded at TICI 3 result. Results 67-year-old male developed left MCA syndrome in the setting of an infected abdominal aortic endograft. A transfemoral approach was ruled out due to concern for crossing the infected endograft. Allen test and ultrasound demonstrated that the right radial artery was of adequate size for access, but the ulnar artery was insufficient to support the palmar arch. Mechanical thrombectomy via ulnar artery access was performed to preserve the dominant radial artery. Systematic review of the literature yielded 2 case series of transulnar neurovascular procedures. Access site complications were rare and included 3 access site hematomas and 1 ulnar artery occlusion. Conclusion We report our technique of serial dilation of the ulnar artery for neuroendovascular procedures and provide a systematic review of the literature for complication avoidance in ulnar artery access. Literature review of ulnar artery access for endovascular neuro-intervention A) Ulnar artery angiogram demonstrates normal-caliber radial artery (black arrow) with small caliber ulnar artery (white arrow). B) Left internal carotid artery angiogram demonstrates left M1 segment middle cerebral artery occlusion. C) Left common carotid artery angiogram demonstrates recanalization of left M1 segment after thrombectomy. D) Ulnar artery angiogram demonstrates occlusion of the ulnar artery (white arrow) in the forearm with normal caliber radial artery (black arrow) Disclosures M. Brandel: None. A. Wali: None. C. McCann: None. B. Tucker: None. S. Olson: None. J. Steinberg: None. D. Santiago-Dieppa: None. A. Khalessi: None. J. Pannell: None.
- Top Cited PapersOpen Access
- 5 January 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e41812
FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (FAST-01): Protocol for the First Prospective Feasibility Study
Background: In preclinical studies, FLASH therapy, in which radiation delivered at ultrahigh dose rates of ≥40 Gy per second, has been shown to cause less injury to normal tissues than radiotherapy delivered at conventional dose rates. This paper describes the protocol for the first-in-human clinical investigation of proton FLASH therapy. Objective: FAST-01 is a prospective, single-center trial designed to assess the workflow feasibility, toxicity, and efficacy of FLASH therapy for the treatment of painful bone metastases in the extremities. Methods: Following informed consent, 10 subjects aged ≥18 years with up to 3 painful bone metastases in the extremities (excluding the feet, hands, and wrists) will be enrolled. A treatment field selected from a predefined library of plans with fixed field sizes (from 7.5 cm × 7.5 cm up to 7.5 cm × 20 cm) will be used for treatment. Subjects will receive 8 Gy of radiation in a single fraction—a well-established palliative regimen evaluated in prior investigations using conventional dose rate photon radiotherapy. A FLASH-enabled Varian ProBeam proton therapy unit will be used to deliver treatment to the target volume at a dose rate of ≥40 Gy per second, using the plateau (transmission) portion of the proton beam. After treatment, subjects will be assessed for pain response as well as any adverse effects of FLASH radiation. The primary end points include assessing the workflow feasibility and toxicity of FLASH treatment. The secondary end point is pain response at the treated site(s), as measured by patient-reported pain scores, the use of pain medication, and any flare in bone pain after treatment. The results will be compared to those reported historically for conventional dose rate photon radiotherapy, using the same radiation dose and fractionation. Results: FAST-01 opened to enrollment on November 3, 2020. Initial results are expected to be published in 2022. Conclusions: The results of this investigation will contribute to further developing and optimizing the FLASH-enabled ProBeam proton therapy system workflow. The pain response and toxicity data acquired in our study will provide a greater understanding of FLASH treatment effects on tumor responses and normal tissue toxicities, and they will inform future FLASH trial designs. Trial Registration: : ClinicalTrials.gov NCT04592887; http://clinicaltrials.gov/ct2/show/NCT04592887 International Registered Report Identifier (IRRID): DERR1-10.2196/41812
- 5 January 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e41812
Top Cited PapersOpen AccessFLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (FAST-01): Protocol for the First Prospective Feasibility Study
Background: In preclinical studies, FLASH therapy, in which radiation delivered at ultrahigh dose rates of ≥40 Gy per second, has been shown to cause less injury to normal tissues than radiotherapy delivered at conventional dose rates. This paper describes the protocol for the first-in-human clinical investigation of proton FLASH therapy. Objective: FAST-01 is a prospective, single-center trial designed to assess the workflow feasibility, toxicity, and efficacy of FLASH therapy for the treatment of painful bone metastases in the extremities. Methods: Following informed consent, 10 subjects aged ≥18 years with up to 3 painful bone metastases in the extremities (excluding the feet, hands, and wrists) will be enrolled. A treatment field selected from a predefined library of plans with fixed field sizes (from 7.5 cm × 7.5 cm up to 7.5 cm × 20 cm) will be used for treatment. Subjects will receive 8 Gy of radiation in a single fraction—a well-established palliative regimen evaluated in prior investigations using conventional dose rate photon radiotherapy. A FLASH-enabled Varian ProBeam proton therapy unit will be used to deliver treatment to the target volume at a dose rate of ≥40 Gy per second, using the plateau (transmission) portion of the proton beam. After treatment, subjects will be assessed for pain response as well as any adverse effects of FLASH radiation. The primary end points include assessing the workflow feasibility and toxicity of FLASH treatment. The secondary end point is pain response at the treated site(s), as measured by patient-reported pain scores, the use of pain medication, and any flare in bone pain after treatment. The results will be compared to those reported historically for conventional dose rate photon radiotherapy, using the same radiation dose and fractionation. Results: FAST-01 opened to enrollment on November 3, 2020. Initial results are expected to be published in 2022. Conclusions: The results of this investigation will contribute to further developing and optimizing the FLASH-enabled ProBeam proton therapy system workflow. The pain response and toxicity data acquired in our study will provide a greater understanding of FLASH treatment effects on tumor responses and normal tissue toxicities, and they will inform future FLASH trial designs. Trial Registration: : ClinicalTrials.gov NCT04592887; http://clinicaltrials.gov/ct2/show/NCT04592887 International Registered Report Identifier (IRRID): DERR1-10.2196/41812